Union Calendar No. 556
115th CONGRESS 2d Session |
[Report No. 115–721, Part I]
To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.
April 23, 2018
Mr. Carter of Georgia (for himself, Mr. Loebsack, and Mr. Reed) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
June 8, 2018
Additional sponsors: Mr. Michael F. Doyle of Pennsylvania, Mrs. Blackburn, Mr. Walden, and Mr. McHenry
June 8, 2018
Reported from the Committee on Energy and Commerce with an amendment
[Strike out all after the enacting clause and insert the part printed in italic]
June 8, 2018
The Committee on Ways and Means discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed
[For text of introduced bill, see copy of bill as introduced on April 23, 2018]
To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SEC. 2. Study on abuse-deterrent opioid formulations access barriers under Medicare.
(a) In general.—Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, the price of such formulations, and prior authorization requirements.
(b) Definition of abuse-deterrent opioid formulation.—In this section, the term “abuse-deterrent opioid formulation” means an opioid that is a prodrug or that has certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.
Union Calendar No. 556 | |||||
| |||||
[Report No. 115–721, Part I] | |||||
A BILL | |||||
To direct the Secretary of Health and Human Services to conduct a study and submit a report on
barriers to accessing abuse-deterrent opioid formulations for individuals
enrolled in a plan under part C or D of the Medicare program. | |||||
June 8, 2018 | |||||
Reported from the Committee on Energy and Commerce with an amendment | |||||
June 8, 2018 | |||||
The Committee on Ways and Means discharged; committed to the Committee of the Whole House on the State of the Union and ordered to
be printed |